Maxim Group Upgrades CNS Pharma to Buy, Announces $20 Price Target
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
Maxim Group analyst Jason McCarthy upgrades CNS Pharma (NASDAQ:CNSP) from Hold to Buy and announces $20 price target.
Maxim Group analyst Jason McCarthy upgrades CNS Pharma (NASDAQ:CNSP) from Hold to Buy and announces $20 price target.